What Management needs to do RIGHT NOW and what they need to

New Post Public Reply Private Reply Replies (1) Message Board
crookedneck
What Management needs to do RIGHT NOW and what they need to stop doing RIGHT NOW!

What we await is news about how they are working with the FDA to help set the new standard for CBD products and an update on our CBD Initiative. If management has any business sense whatsoever, they should have taken the initiative to contact the FDA about their CBD Initiative and see how their approach stacks up to what the FDA wants. The goal would be to align themselves to what the FDA seeks for CBD products. It is critical to start a relationship with the FDA to align themselves to their objectives for CBD in order to get a green light from them that would put NRTI above all the other CBD companies. It would also attract much attention from investors and outside interest that is desperately needed at this point. All this would bolster their position with Nulief and prepare them for a national roll out.

It would also be very wise to develop a plan for securing enough funds to launch Nulief, while conserving some of the funds used to promote their other brands. They could continue with a limited budget for promoting Bikini Ready and still grow the brand, but nothing is more important than preparing for a REAL LAUNCH for Nulief. Getting ahead of everyone else by taking the initiative to develop a working relationship with the FDA now will lead to much greater success for Nulief and their CBD Initiative later on. The FDA moves at a snails pace to approve anything, thus the reason to start NOW!

Some may say "Put a fork in it", but they obviously haven't done any DD to see the huge opportunity that still exist for NRTI with their CBD Initiative. We have the manufacturing process and retail infrastructure already in place, with huge support and endorsements from their Advisory board to make their CBD a huge success. The icing on the cake would be the nod from the FDA on their Nulief CBD product. We have the distinct possibility of becoming the first CBD company to receive FDA support, which would send the share price rocketing upward. This is why Kras should be thinking this through and taking a proactive approach with the FDA right now.

I have also worked in the pharmaceutical division for P&G for 10+ years, until they sold their pharmaceutical division to Warner Chilcott, so I do have some extensive experience in this area, as well as on the retail side. I have learned what works and what doesn't, as well as many tricks of the trade to give one the best shot for success and one of them is to develop a relationship with the FDA early on to get leg up on the competition. Which is why I suggest NRTI does the same right now to get ahead of the game.

The way I see it, this is a do or die situation for NRTI, whereas, if they take the proper steps to get Nulief to retail ahead of competition and keep us informed about their CBD Initiative along the way, we will come back with a flurry, but if we are kept in the dark and the company concentrates more on their other brands instead of their CBD Initiative, we are dead in the water! In a nutshell, that is what it all boils down to and why it is imperative that Kras work with the FDA now and give shareholders a complete update on their CBD Initiative. That is what the market is screaming for and needs, so why not give the market what it wants? If you do the share price goes up, but if not and you continue to ram the other brands down our throats with continual PR's, the share price will languish and eventually keep going lower and lower.

Wait and bundle the news for a whole quarter on all the other brands like Bikini Ready, Slim Trim, Surgex, etc., which will not only save money, but also stop hurting the share price. That should be extremely evident by now and when something isn't working you analyze the situation and make a change! That is what GREAT MANAGEMENT does, they change what isn't working and they sure as hell don't keep doing what isn't working! It is also necessary to keep the market apprised of what is going on with they are most interested in, which is your CBD Initiative. DO THAT AND OUR SHARE PRICE WILL CONTINUE TO RISE, DON'T AND THE SHARE PRICE WILL SUFFER!

If management can get that and act accordingly, we are in for an exciting rest of the year. I mean come on it that hard to do and it only make sense if you want the company to succeed and build shareholder value! Let's see which approach they take! Cheers!

Inergetics Inc. (NRTI) Stock Research Links

NRTI Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

APEC's Shared-Prosperity Message Needs More Detail

Updated Category News Views 13

Geese make handsome symbols, but markets cannot underwrite a metaphor. The Nov. 18, 2026 report from Xinhua News Agency looks back to remarks Chinese President Xi Jinping made 12 years ago, when he used swan geese to urge APEC economies toward greater cooperation and a new collective flight. Its present-day message is plainly hopeful: the APEC family is moving across the...

Continue Reading
AES Clears FERC, Nearing Its December 2 Takeover Close

Updated Category News Views 119

One more regulatory gate just swung open for AES, and this deal is finally staring at the finish line instead of wandering through the usual approval swamp. The Federal Energy Regulatory Commission has issued its final order approving AES's acquisition by a consortium led by Global Infrastructure Partners, part of BlackRock, and EQT Infrastructure VI. The last major...

Continue Reading
Inhibrx Ewing Data Gives Ozekibart a Real Clinical Signal

Updated Category News Views 131

Numbers this lopsided in relapsed Ewing sarcoma make me sit up straight, even after years of watching oncology releases try to turn every blip into a brass band. Inhibrx has reported updated Phase 1/2 data for ozekibart, paired with irinotecan and temozolomide, that look genuinely notable in a disease where patients have very few good cards left to play. That matters...

Continue Reading
FULC, DSGR and OPCH Deals Draw Fresh Shareholder Scrutiny

Updated Category News Views 85

Three proposed transactions have drawn the kind of legal glare that makes shareholders sit up and check the fine print twice. On November 18, 2026, Halper Sadeh LLC said it was investigating deals involving Fulcrum Therapeutics, Distribution Solutions Group, and Option Care Health for possible federal securities-law violations or fiduciary-duty breaches. That is not a...

Continue Reading
Suntory Flowers Tests NASCAR as a Garden Retail Engine

Updated Category News Views 130

Orange sheet metal and flowering vines are an odd couple, which is precisely why this South Florida promotion has some bite. A plant marketer took a hard left turn Suntory Flowers put its Sun Parasol mandevillas alongside DGM Racing at Homestead-Miami Speedway, celebrating the millions of plants grown in South Florida. That is not a conventional horticulture play, and...

Continue Reading
Redseer's $5M Bet on Faster MENA Decision Intelligence

Updated Category News Views 53

Speed has become the expensive commodity in Middle Eastern commerce, and Redseer is putting roughly $5 million behind the idea that executives will pay to get it. Its newly launched Benchmarks MENA 2.0 platform combines proprietary market data with strategic advisory across nine MENA markets. That sounds like another corporate dashboard pitch until you consider the target...

Continue Reading
Anycubic Pushes Toward a Smoother 3D Printing Ecosystem

Updated Category News Views 28

Friction Is the Enemy in Consumer 3D Printing A printer that makes a beautiful object only after three failed attempts is not a consumer product; it is a weekend argument with plastic. That is the useful lens for Anycubic's Formnext 2026 showing in Frankfurt on November 18. The company is not merely rolling out FDM and resin machines at Booth F01 in Hall 12.0. It is...

Continue Reading
Vertex Extends Genomics Pact With $220M in Potential

Updated Category News Views 19

Eight years is long enough to separate a useful science partner from a glossy slide deck, and Vertex’s decision to add four more years with Genomics deserves attention. This is not a splashy acquisition, nor is it a clean revenue number investors can plug into next quarter’s model. It is a deeper commitment to the slow, expensive, wonderfully unforgiving business of...

Continue Reading
Gozney Brings in Armin Boehm for a Global Growth Push

Updated Category News Views 35

A pizza oven company has just made a very grown-up management move. Gozney appointed Armin Boehm as Global President, effective from October 31, putting an experienced consumer-brand operator beside founder, designer and CEO Tom Gozney at a moment when the business says it is becoming a global omnichannel operation. This is not the sort of announcement that comes with...

Continue Reading
Makers Nutrition Credit Puts a Clock on New Brands

Updated Category News Views 196

A few cents per bottle can look downright beautiful when a new supplement brand is staring at its first production bill. Makers Nutrition announced on November 17 a Black Friday manufacturing-credit offer aimed at entrepreneurs and established sellers launching a new formulation, with qualifying new orders eligible for as much as $0.45 per unit through November 29, 2026....

Continue Reading

Top 5 Most Recently Viewed Articles

Investigation Launched into 1st Colonial Bancorp's Sale

Updated Category News Views 256

Exploring the Sale of 1st Colonial Bancorp, Inc. In a significant development for shareholders, the M&A Class Action Firm has initiated an investigation into 1st Colonial Bancorp, Inc. (OTCMKTS: FCOB) regarding its proposed acquisition by Mid Penn Bancorp, Inc. This merger, which has garnered attention in the financial community, raises important questions about the...

Continue Reading
American Tungsten Pursues $10 Million Investment Opportunity

Updated Category News Views 181

American Tungsten Seeks $10 Million Through Private Placement American Tungsten Corp. (CSE:TUNG) (OTCQB:TUNGF) has announced an exciting initiative to raise up to $10 million through a non-brokered private placement, aiming to issue over 2.8 million common shares priced at $3.50 each. This move reflects the heightened demand for critical metals and underscores the...

Continue Reading
Arcadia Biosciences Surpasses Revenue Goals in Q3 2025

Updated Category News Views 188

Arcadia Biosciences Reports Strong Financial Results Arcadia Biosciences, Inc. (NASDAQ: RKDA), a leader in the wellness products sector, recently revealed its financial and operational highlights for the third quarter of 2025. This report showcases the continued growth and resilience of the company amid various market challenges. Year-to-Date Performance As of the third...

Continue Reading
Artificial Superintelligence Alliance Sees Strong Price Gains

Updated Category News Views 71

Overview of Recent Price Movements In the past 24 hours, the price of Artificial Superintelligence Alliance has seen an impressive increase of 5.78%, reaching $1.35. This surge is part of a broader upward trend throughout the week, where it has lifted by 3.0% from $1.33. It's worth noting that the coin's all-time high is recorded at $3.45. Analyzing Volatility and Trends...

Continue Reading
How Bitcoin Boosted Robert Kiyosaki's Wealth Journey

Updated Category News Views 311

Robert Kiyosaki's Insights on Bitcoin Robert Kiyosaki, known for his influential book "Rich Dad Poor Dad," recently shared his experiences and beliefs about Bitcoin, a digital asset he credits for significantly enhancing his wealth. He has gained notoriety as a financial guru, and his comments on Bitcoin have sparked considerable interest in the cryptocurrency market....

Continue Reading